hyperlipidemia based on the standardized interview conducted by the National Center for Health Statistics (NCHS) among adults Ն 18 years. Descriptive statistics and multivariate logistic regression were used to determine predictors having the combined diagnosis including the following independent variables: gender, age, race, ethnicity, urban/rural status and smoking status. Statistical analysis was performed using SAS 9.2. RESULTS: The total sample included 33,994 individuals and the combined diagnosis of hypertension and hyperlipidemia was reported in 4.49% of the sample. Of these, 61.51% were females and 41% were aged between 60-75 years. Most (73.25%) of these patients were whites and more than half (54.75%) reported to have smoked at least 100 cigarettes in their lifetime, while 34.01% were current smokers. In the multivariate model, significant predictors of the combined diagnosis included female gender (ORϭ 0.689; 95% CIϭ 0.594 -0.798; pϽ.0001), age 60-75 years vs. younger age (ORϭ1.627; 95% CIϭ1.296 -2.042; pϽ.0001), Mexican American race vs. non-hispanics (ORϭ 0.611; 95% CIϭ 0.49 -0.76; pϽ.0007) and current smokers. (ORϭ1.374; 95% CIϭ1.08-1.75; pϽ.0001). CONCLUSIONS: Our findings emphasize the importance of developing effective intervention strategies that help smokers quit and may reduce prevalence of hyperlipidemia with hypertension along with the accompanying cardiovascular risk. 
OBJECTIVES:
To study the predictors of beta-blocker therapy discontinuation among post myocardial infarction (MI) patients enrolled in Medicare. METHODS: This is a retrospective cohort study utilizing a Medicare 5% national sample claims data for [2006] [2007] . Medicare beneficiaries with continuous Part A, B, and D enrollment in 2006ϭ2007, and who were hospitalized for an acute MI in the first six months of 2006 were identified using a validated algorithm, requiring a hospitalization episode Ն3 and Յ180 days with an ICD-9-CM of 410.x1 as principal or secondary diagnosis. Post-MI patients with a filled prescription for beta-blocker within 90 days of discharge were followed until the end of the study period. Time to discontinuation was defined as days from initiation of therapy to a gap of Ͼ90 days in therapy. Survival curves were modeled using the Kaplan-Meier technique, and potential predictors of therapy discontinuation, including demographic characteristics, comorbid conditions and concomitant medications were estimated using Cox proportional hazards regression. RESULTS: Of the 2,505 subjects who met our inclusion criteria, 65.1% were females, 83.3% were Caucasian, mean age 78.6 (Ϯ8.2) years. About 15% of them discontinued therapy within six months and around 35% discontinued within a year. Males were more likely to discontinue therapy as compared to females (HRϭ1. OBJECTIVES: Adherence to chronic heart failure (CHF) medications decreases preventable hospitalizations. Nevertheless, CHF rarely occurs without concomitant conditions. We sought to: 1) evaluate impact of comorbid depression on CHF medication use and adherence among Medicare beneficiaries with CHF(CHF_MED-_BEN); 2) examine relationships between CHF medication adherence and outcomes; and 3) determine if depression modifies this relationship. METHODS: We employed a cross-sectional design of 2006-2007 CMS Medicare Chronic Condition Warehouse (CCW) database. Sample was restricted to CHF_MED_BEN with Medicare A,B and D to observe all prescription and medical claims. We classified individuals with CHF and depression if they met the CCW definitions. Adherence measures included any use (binary) and medication possession ratio (MPR) for evidence-based CHF medications (EBM). Multivariable analyses included an interaction term to test effect modification of depression on the relationship between EBM adherence and number of hospitalizations. Relative rates of hospitalization are reported with 95%CI. RESULTS: A total of 151,924 CHF_MED_BEN met inclusion criteria. Mean age was 75.9ϩ/-12.0 years; 68% were female. 25% had depression and they were significantly younger(74.5 vs. 76.3 years,pϽ0.001) and more likely to be female(75% vs. 66%,pϽ0.001) compared to non-depressed CHF_MED_BEN. A significantly lower proportion of depressed CHF_MED_BEN received EBM (75% vs. 79%,pϽ0.001), compared to non-depressed CHF_MED_BEN. Median MPR was 0.92 in both groups. A higher proportion of depressed CHF_MED_BEN was hospitalized (76% vs. 63%,pϽ0.001) and re-hospitalized (40.5% vs. 38.6%,pϽ0.001) compared to non-depressed CHF_MED_BEN. In multivariable models, depression modified the effect of adherence on hospitalizations (interaction term pϽ0.001): compared to high adherence (MPRՆ0.9), poor adherence (MPRϽ0.5) was associated with a 24% (95%CI 1.20-1.28) increased hospitalization rate among non-depressed CHF_MED-_BEN and a 45% (95%CI 1.37-1.54) increased hospitalization rate among depressed CHF_MED_BEN. CONCLUSIONS: Depression was not associated with poor EBM adherence among CHF_MED_BEN. Poor EBM adherence was associated with increased hospitalization in both depressed and non-depressed groups, with a greater effect among depressed CHF_MED_BEN. 
PCV19 A BAYESIAN MULTIPLE TREATMENT COMPARISON OF PULMONARY ARTERIAL HYPERTENSION DRUG CLASSES BASED ON THE RISK OF MORTALITY REPORTED IN CLINICAL TRIALS

OBJECTIVES:
To compare the performance of pulmonary arterial hypertension (PAH) drug classes based on the risk of mortality reported in clinical trials, and inform a revised PAH treatment algorithm. METHODS: The study used Bayesian Analysis Using Gibbs Sampling in Windows (WinBUGS) and Monte Carlo Simulations to conduct a multiple treatment comparison of placebo and three PAH drug classes; prostanoids (Treprostinil & Iloprost), endothelin-receptor antagonists (Bosentan, Sitaxsentan, & Ambrisentan), and phosphodiesterase (sildenafil). Direct and indirect pairwise odds ratios (OR) were obtained. Published PAH studies through 2010 were identified from MEDLINE (PubMed) database and an extended manual search was also conducted based on references from identified studies. Inclusion was restricted to randomized controlled trials lasting at least 12 weeks and at most 16 weeks, with subjects having either idiopathic or associated PAH, and studies that reported mortality as an endpoint. Studies that compared combinations of drugs were excluded from the analysis. Results are reported in OR with 95% credible intervals. RESULTS: In total 8 studies (20 treatment arms, 2,015 subjects enrolled) were included in the analysis. 2 studies were 3-arm trials and 1 was a 4-arm trial. With placebo as the reference class, the OR of mortality was 1.00 (0.06, 4.20) for prostanoids; 1.14 (0.15, 4.69) for endothelin-receptor antagonists and 0.62 (0.05, 2.83) for phosphodiesterase. Using prostanoids as the reference class, the OR of mortality was 4.28 (0.10, 23.10) for endothelin-receptor antagonists and 2.40 (0.04, 12.66) for phosphodiesterase. Using endothelin-receptor antagonists as the reference class, the OR of mortality was 1.11 (0.04, 5.55) for phosphodiesterase. None of the ORs were statistically significant. CONCLUSIONS: Based on the risk of mortality reported in clinical trials, there is no statistically significant difference among PAH drug classes. Including more studies/drugs and the use of different PAH outcomes could inform a more detailed comparison.
PCV20 PERSISTENCE WITH STATINS AND PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS: A POPULATION-BASED COHORT STUDY
Chodick G, Shalev V, Goldstein I, Porath A, Simah V Maccabi Healthcare Services, Tel Aviv, Israel OBJECTIVES: To evaluate the association between persistent use of statins and the risk of acute cardiovascular events among primary prevention patients in community settings. METHODS: A population-based retrospective cohort among 171,846 adults aged 45-75, with no history of any cardiovascular disease, who began statin therapy between 1998 and 2009. Proportion of days covered (PDC) with statins was measured by the number of dispensed prescriptions during follow-up period. Study endpoint was occurrence of a major cardiovascular event, which comprised myocardial infarction or performance of a cardiac revascularization procedure RESULTS: The fully adjusted survival analysis indicated a significant negative as-A35 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4 
